HPTLC estimation of tizanidine and diclofenac sodium in combination tablets

M.K. Senthil, G. Subramanian, M. Vasudevan, S. Ravisankar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A high performance thin layer chromatographic method was developed for the simultaneous estimation of Tizanidine and Diclofenac in tablet formulations. The separation was achieved by precoated Silicagel F254 and the solvent system used for the separation was chloroform and methanol (80:20 v/v) as eluent. The detection was carried out at 230 nm. Cetirizine was used as an internal standard. The solvent system was found to give compact spots for diclofenac sodium (Rf value of 0.86±0.01), tizanidine (0.26±0.01) and cetirizine (0.52±0.02). The method has been validated for linearity accuracy and precision. Linearity for tizanidine and diclofenac sodium were in the range of 0.6-1.4 μg/ml and 7.5-17.5 μg/ml, respectively. The mean recoveries obtained for tizanidine and diclofenac sodium were 98.73% and 99.70%, respectively. The proposed method was accurate, precise, selective and rapid for simultaneous estimation of tizanidine and diclofenac sodium in tablets.
Original languageEnglish
Pages (from-to)465-468
Number of pages4
JournalIndian Drugs
Volume42
Issue number7
Publication statusPublished - 2005

Fingerprint

Diclofenac
Tablets
Cetirizine
Chloroform
Methanol
tizanidine

Cite this

Senthil, M. K., Subramanian, G., Vasudevan, M., & Ravisankar, S. (2005). HPTLC estimation of tizanidine and diclofenac sodium in combination tablets. Indian Drugs, 42(7), 465-468.
Senthil, M.K. ; Subramanian, G. ; Vasudevan, M. ; Ravisankar, S. / HPTLC estimation of tizanidine and diclofenac sodium in combination tablets. In: Indian Drugs. 2005 ; Vol. 42, No. 7. pp. 465-468.
@article{501bf0a5d8f7456793424274ee48f30b,
title = "HPTLC estimation of tizanidine and diclofenac sodium in combination tablets",
abstract = "A high performance thin layer chromatographic method was developed for the simultaneous estimation of Tizanidine and Diclofenac in tablet formulations. The separation was achieved by precoated Silicagel F254 and the solvent system used for the separation was chloroform and methanol (80:20 v/v) as eluent. The detection was carried out at 230 nm. Cetirizine was used as an internal standard. The solvent system was found to give compact spots for diclofenac sodium (Rf value of 0.86±0.01), tizanidine (0.26±0.01) and cetirizine (0.52±0.02). The method has been validated for linearity accuracy and precision. Linearity for tizanidine and diclofenac sodium were in the range of 0.6-1.4 μg/ml and 7.5-17.5 μg/ml, respectively. The mean recoveries obtained for tizanidine and diclofenac sodium were 98.73{\%} and 99.70{\%}, respectively. The proposed method was accurate, precise, selective and rapid for simultaneous estimation of tizanidine and diclofenac sodium in tablets.",
author = "M.K. Senthil and G. Subramanian and M. Vasudevan and S. Ravisankar",
note = "Cited By :5 Export Date: 10 November 2017 CODEN: INDRB Correspondence Address: Subramanian, G.; Manipal College of Pharmaceutical Sciences, Manipal - 576104, India; email: g.subbu@cops.manipal.edu References: Reddy, K.S.S.R.K., Babu, M.J., Dubey, P.K., Shekar, B.C., Reddy, O.G., Vyas, K., Isolation and characterization of Process-related Impurities in Rofecoxib (2002) J. Pharm. Biomed. Anal., 29, p. 355; Reynolds, J.E.F., (1989) Martindale, the Extra Pharmacopoeia, p. 31. , 29th Edn,, Pharmaceutical Press, London; Radhakrishna, T., Rao, S.D., Reddy, G.O., LC Determination of Rofecoxib in Bulk and Pharmaceutical Formulation (2001) J. Pharm. Biomed. Anal., 26, p. 617; Aruna, A., Anusuya, P., Balamarriappan, C., Lakshmanan, M.K., Nanjappan, K., Kumarpavan, A.R., Reverse phase HPLC Determination of Rofecoxib in Tablets (2001) Indian Drugs, 38, p. 523; Woolf, E., Fu, I., Matuszeweski, B., Determination of Rofecoxib, a Cycloxygenase-2-specific inhibitor, in human plasma using high performance liquid chromatography with post-Column Photochemical Derivatization and Fluoresence Detection (1999) J. Chromtatogr. B. Biomed Sci. Appl., 730, p. 221; Chevez-Eng, C.M., Constanzer, M.L., Matuszeweski, B., Determination of Rofecoxib(MK-0996), a cycloxygenase-2-inhibitor in human plasma by high performance liquid chromatography with tandem mass spectrometric detection (2000) J. Chromtatogr. B. Biomed Sci. Appl., 748, p. 38; Shingare, M.S., Naidu, K.R., Kale, U.N., Reverse phase HPLC method for the simultaneous estimation of Tizanidine Hydrochloride and Nimesulide in Tablets (2003) Indian J. Pharm. Sci., 65, p. 315; Tuncel, M., Dogrulol, D., Electroanalytical behaviour of tizanidine (1992) Anal. Lett., 25, p. 1087; Bouklouge, A.A., El Jammal, A., Vire, J.C., Patriache, G.J., Comparative study of three Polymeric membrane electrodes selective to Tizanidine (1992) Anal. Chim., Acta, 257, p. 41; Bhoir, I.C., Raman, B., Sundaresan, M., Bhagawat, A.M., (1998) Anal. Lett., 31, p. 1533; International Conference on Harmonization, Guidance for Industry (1996) Q2B Validation on Analytical Procedures: Methodology, p. 2",
year = "2005",
language = "English",
volume = "42",
pages = "465--468",
journal = "Indian Drugs",
issn = "0019-462X",
publisher = "Indian Drug Manufacturers' Association",
number = "7",

}

Senthil, MK, Subramanian, G, Vasudevan, M & Ravisankar, S 2005, 'HPTLC estimation of tizanidine and diclofenac sodium in combination tablets', Indian Drugs, vol. 42, no. 7, pp. 465-468.

HPTLC estimation of tizanidine and diclofenac sodium in combination tablets. / Senthil, M.K.; Subramanian, G.; Vasudevan, M.; Ravisankar, S.

In: Indian Drugs, Vol. 42, No. 7, 2005, p. 465-468.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HPTLC estimation of tizanidine and diclofenac sodium in combination tablets

AU - Senthil, M.K.

AU - Subramanian, G.

AU - Vasudevan, M.

AU - Ravisankar, S.

N1 - Cited By :5 Export Date: 10 November 2017 CODEN: INDRB Correspondence Address: Subramanian, G.; Manipal College of Pharmaceutical Sciences, Manipal - 576104, India; email: g.subbu@cops.manipal.edu References: Reddy, K.S.S.R.K., Babu, M.J., Dubey, P.K., Shekar, B.C., Reddy, O.G., Vyas, K., Isolation and characterization of Process-related Impurities in Rofecoxib (2002) J. Pharm. Biomed. Anal., 29, p. 355; Reynolds, J.E.F., (1989) Martindale, the Extra Pharmacopoeia, p. 31. , 29th Edn,, Pharmaceutical Press, London; Radhakrishna, T., Rao, S.D., Reddy, G.O., LC Determination of Rofecoxib in Bulk and Pharmaceutical Formulation (2001) J. Pharm. Biomed. Anal., 26, p. 617; Aruna, A., Anusuya, P., Balamarriappan, C., Lakshmanan, M.K., Nanjappan, K., Kumarpavan, A.R., Reverse phase HPLC Determination of Rofecoxib in Tablets (2001) Indian Drugs, 38, p. 523; Woolf, E., Fu, I., Matuszeweski, B., Determination of Rofecoxib, a Cycloxygenase-2-specific inhibitor, in human plasma using high performance liquid chromatography with post-Column Photochemical Derivatization and Fluoresence Detection (1999) J. Chromtatogr. B. Biomed Sci. Appl., 730, p. 221; Chevez-Eng, C.M., Constanzer, M.L., Matuszeweski, B., Determination of Rofecoxib(MK-0996), a cycloxygenase-2-inhibitor in human plasma by high performance liquid chromatography with tandem mass spectrometric detection (2000) J. Chromtatogr. B. Biomed Sci. Appl., 748, p. 38; Shingare, M.S., Naidu, K.R., Kale, U.N., Reverse phase HPLC method for the simultaneous estimation of Tizanidine Hydrochloride and Nimesulide in Tablets (2003) Indian J. Pharm. Sci., 65, p. 315; Tuncel, M., Dogrulol, D., Electroanalytical behaviour of tizanidine (1992) Anal. Lett., 25, p. 1087; Bouklouge, A.A., El Jammal, A., Vire, J.C., Patriache, G.J., Comparative study of three Polymeric membrane electrodes selective to Tizanidine (1992) Anal. Chim., Acta, 257, p. 41; Bhoir, I.C., Raman, B., Sundaresan, M., Bhagawat, A.M., (1998) Anal. Lett., 31, p. 1533; International Conference on Harmonization, Guidance for Industry (1996) Q2B Validation on Analytical Procedures: Methodology, p. 2

PY - 2005

Y1 - 2005

N2 - A high performance thin layer chromatographic method was developed for the simultaneous estimation of Tizanidine and Diclofenac in tablet formulations. The separation was achieved by precoated Silicagel F254 and the solvent system used for the separation was chloroform and methanol (80:20 v/v) as eluent. The detection was carried out at 230 nm. Cetirizine was used as an internal standard. The solvent system was found to give compact spots for diclofenac sodium (Rf value of 0.86±0.01), tizanidine (0.26±0.01) and cetirizine (0.52±0.02). The method has been validated for linearity accuracy and precision. Linearity for tizanidine and diclofenac sodium were in the range of 0.6-1.4 μg/ml and 7.5-17.5 μg/ml, respectively. The mean recoveries obtained for tizanidine and diclofenac sodium were 98.73% and 99.70%, respectively. The proposed method was accurate, precise, selective and rapid for simultaneous estimation of tizanidine and diclofenac sodium in tablets.

AB - A high performance thin layer chromatographic method was developed for the simultaneous estimation of Tizanidine and Diclofenac in tablet formulations. The separation was achieved by precoated Silicagel F254 and the solvent system used for the separation was chloroform and methanol (80:20 v/v) as eluent. The detection was carried out at 230 nm. Cetirizine was used as an internal standard. The solvent system was found to give compact spots for diclofenac sodium (Rf value of 0.86±0.01), tizanidine (0.26±0.01) and cetirizine (0.52±0.02). The method has been validated for linearity accuracy and precision. Linearity for tizanidine and diclofenac sodium were in the range of 0.6-1.4 μg/ml and 7.5-17.5 μg/ml, respectively. The mean recoveries obtained for tizanidine and diclofenac sodium were 98.73% and 99.70%, respectively. The proposed method was accurate, precise, selective and rapid for simultaneous estimation of tizanidine and diclofenac sodium in tablets.

M3 - Article

VL - 42

SP - 465

EP - 468

JO - Indian Drugs

JF - Indian Drugs

SN - 0019-462X

IS - 7

ER -

Senthil MK, Subramanian G, Vasudevan M, Ravisankar S. HPTLC estimation of tizanidine and diclofenac sodium in combination tablets. Indian Drugs. 2005;42(7):465-468.